GLP-1 Group Drugs Open a New Era in the History of Medicine
Drugs such as Ozempic and Wegovy do not only help you lose weight; It was announced that it provides systemic improvements in heart, cancer, respiratory and metabolic diseases.
Quick Look
Experts from Yale School of Medicine announced that GLP-1 group drugs such as Ozempic and Mounjaro reduce the risks of heart attack, stroke, 13 different types of cancer, sleep apnea, asthma and COPD, beyond obesity and type 2 diabetes.
AI-generated summary
Why It Matters
GLP-1 group drugs were initially developed for the treatment of type 2 diabetes and obesity.
GLP-1 (Glucagon-Like Peptide-1) group drugs, which are among the most popular pharmacological developments of recent times, have gone beyond the management of type 2 diabetes and obesity and opened a new era in the history of medicine. Cardiologist Prof. from Yale School of Medicine. Dr. Harlan Krumholz explained that drugs such as Ozempic, Wegovy and Mounjaro not only help you lose weight, but also "rewind time" by regressing many systemic disorders in the body.
FDA APPROVED SHIELD AGAINST HEART ATTACK AND STROKE RISK
The most significant protective effect of GLP-1 drugs is seen on the cardiovascular system. Prof. Dr. These active ingredients, which Krumholz also describes as "heart medicine", significantly reduce the risk of heart attack and stroke in obesity and diabetic patients. The US Food and Drug Administration (FDA) has officially approved the use of these drugs to reduce cardiovascular risks.
It was also noted that tirzepatidine, the active ingredient of Mounjaro, was more effective than existing blood pressure medications by reducing the patients' systolic blood pressure by approximately 7 points. In addition, the drugs have also been confirmed to be effective in the treatment of obstructive sleep apnea, which causes respiratory arrest during sleep.
IT REDUCES THE RISK OF OBESITY-RELATED CANCER BY 41%
A comprehensive clinical study published in 2026 revealed the protective effect of GLP-1 use on cancer cases. In the study conducted on patients without diabetes; It was found that the risk of developing 13 different types of obesity-related cancers, including breast, kidney, intestine, pancreas, thyroid, ovarian, esophagus and liver cancers, was reduced by 41%.
The drugs were also reported to reduce fatty liver disease (MASH), reduce the risk of kidney failure, and improve fertility problems related to polycystic ovary syndrome (PCOS).
IT REDUCES ASTHMA RISKS AND COPD EXACERBATIONS
Another study conducted by experts at Imperial College London in England proved the miraculous effect of the drug on respiratory diseases. It was determined that the rate of attacks in asthma patients using semaglutide decreased by 40%, and lung exacerbations in COPD patients decreased by 20%.
University of California Berkeley researchers remind that the drugs extended lifespan in mice by 12% (about 100 days), emphasizing that the GLP-1 mechanism triggers a cellular rejuvenation line independent of calorie restriction. Experts warn that these drugs should be used under physician supervision and with personalized treatment protocols.
What to Watch
AI outlook — possibilities, not facts
Approval processes for new indications of GLP-1 drugs will continue
Likely · Within months
Open Questions
- What are the long-term side effects?
- Will drug costs decrease?
